Professor Marcellin concluded that TDF produced potent, continuous viral suppression and was well tolerated through 96 weeks. Patients rolling to TDF after 48 weeks of ADV treatment benefited with si...

The classification for liver failure is basically of acute liver failure, that is in a patient with no underlying non-liver disease, the patient gets jaundice and encephalopathy within a period of 4 w...

In the ordinary circumstances, we mainly pay attention to the HBV DNA level during the treatment of hepatitis B. But HBV DNA is not the target of the immune response; the immune response is antigen-an...

I think there is still a place for interferon and interferon might even come back into the arena of antiviral treatment because it is a drug that definitely creates immune control and offtreatment sus...

Hepatitis C virus infection is a principal etiological agent of liver cancer in the world. Professor T. Jake Liang, from the Liver Diseases Branch, NIDDK, NIH, USA, presented a report on hepatitis C a...

Professor Wang pointed out that the efficacy of antiviral therapy by nucleos(t)ide analogues, particularly lamivudine (LAM), for HBV-associated hepatic failure hepatitis B has been well demonstrated. ...

Professor Kim pointed out that several factors associated with severe recurrent hepatitis C had been identified. Older donor age and administration of OKT-3 or bolus doses of corticosteroids are the s...

High levels of HBV replication are associated with increased risk of cirrhosis, decompensation, hepatocellular carcinoma and liver related mortality. In addition, long-term studies of antiviral therap...

In this session, several issues focusingon immunology in viral hepatitis were included: an update of HBV vaccine, from the innate to adaptive immune response and the characteristics of hepatitis B vir...

On the fourth day of APASL, Professor Michael P. Manns presented a lecture on advances in hepatitis C infection. He said that in recent years, therapy for hepatitis C had been optimized by individuali...

Chronic hepatitis B is a prevalent disease worldwide, especially in Asia. Long term follow-up studies show that the persistent exposure to high viral load is the major driving force for disease progre...

The debate between Professor Schiff and Professor Jia brought us insight into the current state of NAs therapy. If we review the current guidelines of management of chronic hepatitis B, we can find th...

In a chronic HBV carrier, chronic hepatitis B is defined by an elevated serum HBV DNA. The goal of chronic hepatitis B therapy is to prevent progression of liver disease to its complications. This can...

Professor Bowden pointed out that measurement of viral load was indispensable for monitoring and confirming the presence of NRTI resistant virus, since nearly all instances of resistance to NRTI were ...